Groesbeck P Parham1, Mulindi H Mwanahamuntu2, Vikrant V Sahasrabuddhe3, Andrew O Westfall4, Kristin E King5, Carla Chibwesha6, Krista S Pfaendler7, Gracilia Mkumba2, Victor Mudenda8, Sharon Kapambwe2, Sten H Vermund9, Michael L Hicks10, Jeffrey Sa Stringer6, Benjamin H Chi6. 1. University of Alabama at Birmingham, AL, USA ; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia ; University Teaching Hospital, Lusaka, Zambia. 2. Centre for Infectious Disease Research in Zambia, Lusaka, Zambia ; University Teaching Hospital, Lusaka, Zambia. 3. Vanderbilt University, TN, USA ; National Cancer Institute, MD, USA. 4. Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. 5. University of Michigan, MI, USA. 6. University of Alabama at Birmingham, AL, USA ; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. 7. University of Cincinnati, OH, USA. 8. University Teaching Hospital, Lusaka, Zambia. 9. Vanderbilt University, TN, USA. 10. Michigan Cancer Institute, MI, USA.
Abstract
BACKGROUND: Cervical cancer kills more women in low-income nations than any other malignancy. A variety of research and demonstration efforts have proven the efficacy and effectiveness of low-cost cervical cancer prevention methods but none in routine program implementation settings of the developing world, particularly in HIV-infected women. METHODS: In our public sector cervical cancer prevention program in Zambia, nurses conduct screening using visual inspection with acetic acid aided by digital cervicography. Women with visible lesions are offered same-visit cryotherapy or referred for histologic evaluation and clinical management. We analyzed clinical outcomes and modeled program effectiveness among HIV-infected women by estimating the total number of cervical cancer deaths prevented through screening and treatment. RESULTS: Between 2006 and 2008, 6572 HIV-infected women were screened, 53.6% (3523) had visible lesions, 58.5% (2062) were eligible for cryotherapy and 41.5% (1461) were referred for histologic evaluation. A total of 75% (1095 out of 1462) of patients who were referred for evaluation complied. Pathology results from 65% (715 out of 1095) of women revealed benign abnormalities in 21% (151), cervical intraepithelial neoplasia (CIN) I in 30% (214), CIN 2/3 in 33% (235) and invasive cervical cancer in 16.1% (115, of which 69% were early stage). Using a conditional probability model, we estimated that our program prevented 142 cervical cancer deaths (high/low range: 238-96) among the 6572 HIV-infected women screened, or one cervical cancer death prevented per 46 (corresponding range: 28-68) HIV-infected women screened. CONCLUSION: Our prevention efforts using setting-appropriate human resources and technology have reduced morbidity and mortality from cervical cancer among HIV-infected women in Zambia. Financial support for implementing cervical cancer prevention programs integrated within HIV/AIDS care programs is warranted. Our prevention model can serve as the implementation platform for future low-cost HPV-based screening methods, and our results may provide the basis for comparison of programmatic effectiveness of future prevention efforts.
BACKGROUND:Cervical cancer kills more women in low-income nations than any other malignancy. A variety of research and demonstration efforts have proven the efficacy and effectiveness of low-cost cervical cancer prevention methods but none in routine program implementation settings of the developing world, particularly in HIV-infectedwomen. METHODS: In our public sector cervical cancer prevention program in Zambia, nurses conduct screening using visual inspection with acetic acid aided by digital cervicography. Women with visible lesions are offered same-visit cryotherapy or referred for histologic evaluation and clinical management. We analyzed clinical outcomes and modeled program effectiveness among HIV-infectedwomen by estimating the total number of cervical cancer deaths prevented through screening and treatment. RESULTS: Between 2006 and 2008, 6572 HIV-infectedwomen were screened, 53.6% (3523) had visible lesions, 58.5% (2062) were eligible for cryotherapy and 41.5% (1461) were referred for histologic evaluation. A total of 75% (1095 out of 1462) of patients who were referred for evaluation complied. Pathology results from 65% (715 out of 1095) of women revealed benign abnormalities in 21% (151), cervical intraepithelial neoplasia (CIN) I in 30% (214), CIN 2/3 in 33% (235) and invasive cervical cancer in 16.1% (115, of which 69% were early stage). Using a conditional probability model, we estimated that our program prevented 142 cervical cancer deaths (high/low range: 238-96) among the 6572 HIV-infectedwomen screened, or one cervical cancer death prevented per 46 (corresponding range: 28-68) HIV-infectedwomen screened. CONCLUSION: Our prevention efforts using setting-appropriate human resources and technology have reduced morbidity and mortality from cervical cancer among HIV-infectedwomen in Zambia. Financial support for implementing cervical cancer prevention programs integrated within HIV/AIDS care programs is warranted. Our prevention model can serve as the implementation platform for future low-cost HPV-based screening methods, and our results may provide the basis for comparison of programmatic effectiveness of future prevention efforts.
Entities:
Keywords:
HIV/AIDS; Zambia; cervical cancer; program effectiveness; screening
Authors: Diljeet K Singh; Kathryn Anastos; Donald R Hoover; Robert D Burk; Qiuhu Shi; Louis Ngendahayo; Eugene Mutimura; Antonio Cajigas; Venerand Bigirimani; Xiaotao Cai; Janvier Rwamwejo; Magalis Vuolo; Mardge Cohen; Philip E Castle Journal: J Infect Dis Date: 2009-06-15 Impact factor: 5.226
Authors: Miriam L Cremer; Ethel I Peralta; Selma G Dheming; Maria E Jimenez; Carol A Davis-Dao; Todd A Alonzo; Paul D Blumenthal; Juan C Felix Journal: J Low Genit Tract Dis Date: 2010-01 Impact factor: 1.925
Authors: A L Akinwuntan; O A Adesina; C A Okolo; O A Oluwasola; A Oladokun; A A Ifemeje; I F Adewole Journal: J Obstet Gynaecol Date: 2008-08 Impact factor: 1.246
Authors: V V Sahasrabuddhe; M H Mwanahamuntu; S H Vermund; W K Huh; M D Lyon; J S A Stringer; G P Parham Journal: Br J Cancer Date: 2007-04-17 Impact factor: 7.640
Authors: Claudine Akono Ayissi; Richard G Wamai; Geofrey O Oduwo; Stacey Perlman; Edith Welty; Thomas Welty; Simon Manga; Javier Gordon Ogembo Journal: J Community Health Date: 2012-12
Authors: Renicha McCree; Mary Rose Giattas; Vikrant V Sahasrabuddhe; Pauline E Jolly; Michelle Y Martin; Stuart Lawrence Usdan; Connie Kohler; Nedra Lisovicz Journal: Oncologist Date: 2015-04-29
Authors: Sharon Kapambwe; Vikrant V Sahasrabuddhe; Meridith Blevins; Mulindi H Mwanahamuntu; Victor Mudenda; Bryan E Shepherd; Carla J Chibwesha; Krista S Pfaendler; Michael L Hicks; Sten H Vermund; Jeffrey S A Stringer; Groesbeck P Parham Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731
Authors: Oliver C Ezechi; Chidinma V Gab-Okafor; Per Olof Ostergren; Karen Odberg Pettersson Journal: BMC Public Health Date: 2013-01-17 Impact factor: 3.295
Authors: H Rafferty; A S Sturt; C R Phiri; E L Webb; M Mudenda; J Mapani; P L A M Corstjens; G J van Dam; A Schaap; H Ayles; R J Hayes; L van Lieshout; I Hansingo; A L Bustinduy Journal: BMC Infect Dis Date: 2021-07-17 Impact factor: 3.090